CLLS Cellectis S.A.
Healthcare$3.67+4.86%ClosedMarket Cap: $368.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
6.35
P/S
4.02
EV/EBITDA
-7.72
DCF Value
$-5.40
FCF Yield
-14.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.9%
Operating Margin
-69.2%
Net Margin
-98.7%
ROE
-80.6%
ROA
-23.3%
ROIC
-26.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $5.8M | 21.5% | $-27.1M | $-17.8M | $— | — |
| Q4 null | $10.4M | 71.2% | $-17.4M | $-26.3M | $— | — |
| FY null | $72.9M | 86.6% | $-33.1M | $-67.6M | $— | — |
| Q3 null | $35.2M | 93.3% | $8.0M | $589.0K | $— | — |
| Q2 null | $16.7M | 85.5% | $-9.6M | $-23.7M | $— | — |
| Q1 null | $10.7M | 81.1% | $-14.2M | $-18.1M | $— | — |
| Q4 null | $12.7M | 80.2% | $-10.7M | $5.9M | $— | — |
| FY null | $41.5M | 77.9% | $-59.6M | $-36.8M | $— | — |
| Q3 null | $16.2M | 82.8% | $-10.8M | $-23.1M | $— | — |
| Q2 null | $8.1M | 81.0% | $-17.2M | $-25.3M | $— | — |
| Q1 null | $4.5M | 48.2% | $-20.9M | $5.6M | $— | — |
| Q4 2023 | $283.0K | 41.0% | $-29.6M | $-42.9M | $-0.60 | — |